In addition, mTORC1 inhibition by rapamycin and its analogues often leads to negative feedback hyper-activation of PI3K/AKT [61], thus limiting the therapeutic effects, and depending on the mutations in the tumours, possibly creating a more aggressive phenotype. This evidence concerns the gene AKT1 and neoplasm.